Table I.
Cell Line |
Treatment | Donor | Control | 20% PPC | 100% PPC | 300% PPC |
---|---|---|---|---|---|---|
BT20 | DT | A | 1522 ± 136 | 987 ± 81 | 487 ± 42 | 820 ± 114 |
BT20 | DT | B | 2597 ± 186 | 2222 ± 289 | 1347 ± 97 | 1469 ± 173 |
BT20 | DT | C | 1906 ± 139 | 1147 ± 82 | 914 ± 67 | 624 ± 45 |
BT20 | DOX | A | 2276 ± 116 | 2717 ± 142 | 1857 ± 118 | 1883 ± 110 |
BT20 | DOX | B | 2539 ± 121 | 2499 ± 103 | 1228 ± 100 | 837 ± 59 |
BT20 | DOX | C | 1521 ± 72 | 514 ± 50 | 754 ± 51 | 632 ± 33 |
PC3 | DT | A | 1251 ± 112 | 890 ± 105 | 500 ± 68 | 1043 ± 120 |
PC3 | DT | B | 4260 ± 437 | 4095 ± 300 | 2006 ± 355 | 2006 ± 455 |
PC3 | DT | C | 3992 ± 422 | 3662 ± 400 | 1512 ± 184 | 2020 ± 241 |
PC3 | MTX | A | 6019 ± 572 | 4178 ± 494 | 2529 ± 332 | 2419 ± 332 |
PC3 | MTX | B | 2419 ± 247 | 2721 ± 332 | 1759 ± 224 | 1127 ± 176 |
PC3 | MTX | C | 7778 ± 1039 | 5937 ± 518 | 3848 ± 690 | 5964 ± 861 |